- Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China
- Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023
- Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients
- Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer
- Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®
- Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Macau
More ▼
Key statistics
On Friday, Everest Medicines Ltd (1952:HKG) closed at 20.85, 102.03% above the 52 week low of 10.32 set on Jun 12, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 21.25 |
---|---|
High | 21.30 |
Low | 20.80 |
Bid | 20.80 |
Offer | 20.85 |
Previous close | 20.95 |
Average volume | 2.82m |
---|---|
Shares outstanding | 324.70m |
Free float | 194.05m |
P/E (TTM) | -- |
Market cap | 7.13bn HKD |
EPS (TTM) | -2.92 HKD |
Data delayed at least 15 minutes, as of Jun 07 2024 09:09 BST.
More ▼